How to protect the heart in septic shock: a hypothesis on the pathophysiology and treatment of septic heart failure.
Heart failure is a well-recognized manifestation of organ failure in sepsis and septic shock. The pathophysiology of septic heart failure is complex and currently believed to involve several mechanisms. So far, the contributory role of high plasma catecholamine levels has not been investigated. In this manuscript, we present a hypothesis suggesting that excessive catecholamine production and exogenous administration of catecholamines may relevantly contribute to the development of heart failure and cardiovascular collapse in patients suffering from septic shock. Substantially elevated plasma catecholamine levels were measured during critical illness and sepsis or septic shock. There is a growing body of clinical and experimental evidence demonstrating that high catecholamine plasma levels exert direct toxic effects on the heart. The pathophysiologic mechanisms involved in catecholamine-induced cardiomyocyte toxicity may involve a combination of inflammation, oxidative stress, and abnormal calcium handling resulting in myocardial stunning, apoptosis and necrosis. Clinical signs of catecholamine-induced heart failure can present with a wide range of symptoms reaching from subtle histological changes with preserved myocardial pump function to severe heart failure exhibiting a distinctive echocardiographic pattern which became known as "Takotsubo"-like cardiomyopathy or the left ventricular apical ballooning syndrome. In a medical intensive care unit patient population, presence of sepsis was the only variable associated with the development of left ventricular apical ballooning. Since several therapeutic interventions influence catecholamine plasma levels in septic shock patients, treatment strategies aiming at the reduction of endogenous or exogenous catecholamine exposure may protect the heart during septic shock and could facilitate patient survival.
Schmittinger
Christian A
CA
Department of Anaesthesiology and Critical Care Medicine, Innsbruck Medical University, Innsbruck, Austria.
Wurzinger
Bettina
B
Deutinger
Martina
M
Wohlmuth
Christoph
C
Knotzer
Hans
H
Torgersen
Christian
C
Dünser
Martin W
MW
Hasibeder
Walter R
WR
D002316:Cardiotonic Agents / Q000627:therapeutic use*; D002395:Catecholamines / Q000009:adverse effects* / Q000097:blood*; D006333:Heart Failure / Q000139:chemically induced* / Q000503:physiopathology* / Q000517:prevention & control; D006801:Humans; D008955:Models, Cardiovascular; D012772:Shock, Septic / Q000139:chemically induced* / Q000503:physiopathology* / Q000517:prevention & control
D002316:Cardiotonic Agents; D002395:Catecholamines